IT’S ALL ABOUT YOU
Self-testing health platforms
Our mission is to give every women the option to track their individual health by themselves. Therefore, we develop personalized innovative health-tracking platforms based on latest scientific knowledge and technologies. Our platforms combine innovative in-vitro diagnostic test devices for home use with smart digital technologies and intelligent algorithms.
How we deal with our health is undergoing a substantial change. The increasing health awareness especially of female individuals is boosting the demand for tools that provide us with information about our health. The industry already offers a significant number of smart tools but restricted to lifestyle rather than health in a medical sense.
We develop devices that allow the diagnostic testing of menstrual blood, vaginal fluids and cells and the smart analysis of these health data for self-testing at home as easy as measuring the body temperature. The result will be a platform that provides the female individual personalized information about the development of their health.
Technologies such as new sensors, smart devices and applications have enabled individuals to monitor their health and fitness. These new technologies are currently limited to physiological and fitness-related parameters, such as blood pressure, heartbeat, temperature or step-count data. However, blood-based parameters are the most sensitive and most reliable parameters to monitor health. Yet blood-based parameters have not been accessible for these new technologies in particular for self-testing at home.
With new technologies
We bring these technologies together to give the woman the opportunity to monitor their health development. We integrate in-vitro diagnostic tests to collect individual data and perform diagnoses with smart data analysis and links to scientific knowledge from medical data-bases into small intuitive to use devices for home use. As a result the female individual is getting an interpretation of the deviation from the healthy personal pathway. The deviation will trigger an alert that can be extended to a personalized clinical advice.
Easy to use
The diagnostic devices allow female individuals to run blood-based and cell-based diagnostic tests without pain and without the need of specific training. An app will enable to control the device, to interpret the test results, to create electronic diaries and alerts and optionally to transfer data to telemedical services. Some of our diagnostic devices allow women to perform painless on-the spot medical diagnoses if doubts about their health exist, such as having been infected.
For all women
The platform to track individual’s health can be used by all women. Healthy women can use it to track their health and screen for diseases when in doubt as well as patients that like to screen for the re-occurrence of a diseases or that like to monitor the efficacy of a treatment. The digital interfaces allows our platform to be embedded in telemedical programs in the western world but also in developing countries.
The platforms enable women to take informed and scientifically based decisions about actions to be taken. The implementation of the electronic diary into the electronic health records data base allows women to share the information with their physician.
Early detection matters
Symptoms of illness are usually perceived with a delay. But it’s a scientific fact that the earlier a disease is discovered, the greater the chance of a cure. The way to the doctor and additional laboratory diagnostic steps create further delays on the way to a probably necessary treatment. Our platform therefore makes also a medically valuable contribution to the early detection of diseases.
The paradigm of medicine has changed. The focus was on diagnosing and treating “the” patient. Today the patient is recognized as an individual to be precisely diagnosed and specifically treated. Scientific innovation has enabled and will further enable medicine to turn towards to be more predicative, preventive and personalized. The individual, already well informed by internet information, will be enabled by our self-testing platform to get fact-based precision knowledge about the development of his own individual health. This may change the patient’s paradigm from self-observation to fact-based personalized health information and conscious decision taking.
Dentist and oral surgeon. Habilitation (assistant professorship) in experimental implantology and oral surgery at the University of Zurich. Stefan holds various patents and is initiator and co-founder of numerous spin-off companies. In several multi-disciplinary and ongoing research projects he is involved in the development of a new standard to evaluate and monitor individual risk factors related to different diseases, based on the evaluation of body fluids. Stefan’s major aim and vision is to go off from delayed reactive medical services to evidence-based predictive, preventive and personalized medicine (3P) with comparing historical baseline data unique to each wearer.
PhD in Analytical Chemistry and Bioinformatics from the University of Tübingen. He joined Roche in 2003 to build up Metabonomics. In 2005 Frank joined Novartis and hold positions of increasing responsibility: Responsible for Novartis – FDA biomarker collaborations, director of international consortia (e.g. IMI SAFE-T), translational medicine expert for nephrology and transplantation, leader of the first Novartis personalized medicine teams, and co-founder of the Novartis point of care diagnostic activities resulting in the first-ever Novartis IVD platform launched commercially (Niji). Frank also initiated a collaboration with the BMGF foundation to develop Ebola and ultra-sensitive Malaria tests. Frank has been author of multiple publications in high-impact journals.
PhD in economics of the University of Basel. Christian has experience in the pharmaceutical industry i.a. as Assistant to the Roche President Fritz Gerber. He was CEO of a pharma marketing agency. As founder of the IMK Institute for Medicine and Communication he worked for Swiss medical associations. With Retrieval AG he was involved in the first Swiss digital network for physicians. With Jäggi Communications he published medical periodicals and was engaged in M&A processes in the logistics industry (DHL/Deutsche Post) and worked for engineering and IT companies. He is co-founder of Prosalix AG and BioInitials GmbH and President of DigitalBasel.
Ana Bela Torres
As Neurophysiologist with clinical experience (PT), Ana Bela has a PhD in Stem cells, Tissue Engineering and Regenerative Medicine from the European Headquarters of Excellence in Tissue Engineering and Regenerative Medicine (PT) and ETH Zurich (CH). She is currently group leader at University of Applied Sciences School of Life Sciences, Muttenz (CH), with expertise in biochemical and physical surface functionalization of clinically-relevant polymers as key mediators of stem cell differentiation and angiogenesis, regeneration of central nervous system, and discrimination of gynecological cancer markers.